Brie Bio presents late data from its Phase 2 Henry and Schaffer studies at AASLD 2026, supporting a BRII-179-based preparation and enrichment strategy for functional HBV cure -. Company announcement - FT.com.
Brie Bio presents late data from its Phase 2 Henry and Schaffer studies at AASLD 2026, supporting a BRII-179-based preparation and enrichment strategy for functional HBV cure -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in